Noxopharm Limited is an Australian clinical-stage biotechnology company focused on discovering and developing innovative treatments for cancer and inflammation, as well as advancing mRNA vaccine technologies. The company operates through two preclinical platforms, targeting both oncology and non-oncology therapeutic areas. Noxopharm's research aims to improve patient outcomes by sensitizing cancer cells to radiotherapy and chemotherapy, positioning it at the forefront of novel drug development in the biotech sector. Headquartered in Sydney, Noxopharm is listed on the CHI-X Market Australia - Limit Venue, providing investors access to its shares through this alternative trading platform. The company plays a significant role in Australia’s life sciences industry, contributing to the advancement of clinical-stage therapies and supporting the broader pharmaceutical innovation ecosystem.